J&J To Pay $1.25B For Global Rights To Eczema Treatment
By Henrik Nilsson · May 28, 2024, 9:38 PM EDT
Johnson & Johnson has agreed to buy the rights to an experimental treatment for eczema from Baker McKenzie-advised Numab Therapeutics for approximately $1.25 billion, the companies announced on Tuesday....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login